A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will ...

Novo Nordisk A/S (NYSE:NVO) is one of the top low volatility healthcare stocks to buy now. In a report released on July 17, ...

One in eight Americans use GLP-1 weight-loss drugs, but are they getting the real thing? Novo Nordisk's dramatic exit from a ...

Novo Nordisk trades at a significant discount to Eli Lilly, offering nearly 38% upside. Click here to find out why NVO stock ...

Novo Nordisk A/S (NYSE:NVO) is one of the stocks that Jim Cramer shed light on. A caller asked about the stock’s status, and ...

The U.S. FDA ban on compounded versions of Novo Nordisk's Wegovy has increased its prescriptions by 33%. Despite this, ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

Novo Nordisk Pakistan hosted “Unordinary Partnerships to Shape a Healthier Tomorrow” that brought together healthcare ...

Novo Nordisk A/S (NYSE:NVO) is one of the Best Extremely Profitable Stocks to Buy Right Now. On July 18, Novo Nordisk A/S ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Ongoing patent battle between Novo Nordisk and Dr Reddy’s Laboratories over semaglutide export to multiple countries.